Nxera Pharma Statistics

Total Valuation

Nxera Pharma has a market cap or net worth of JPY 74.98 billion. The enterprise value is 106.78 billion.

Market Cap	74.98B
Enterprise Value	106.78B

Important Dates

The last earnings date was Friday, May 2, 2025.

Earnings Date	May 2, 2025
Ex-Dividend Date	n/a

Share Statistics

Nxera Pharma has 89.90 million shares outstanding. The number of shares has increased by 6.46% in one year.

Current Share Class	89.90M
Shares Outstanding	89.90M
Shares Change (YoY)	+6.46%
Shares Change (QoQ)	-0.00%
Owned by Insiders (%)	10.46%
Owned by Institutions (%)	31.17%
Float	73.00M

Valuation Ratios

PE Ratio	n/a
Forward PE	35.55
PS Ratio	2.43
PB Ratio	1.12
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-46.08
EV / Sales	3.46
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-19.45

Financial Position

The company has a current ratio of 3.72, with a Debt / Equity ratio of 0.99.

Current Ratio	3.72
Quick Ratio	2.83
Debt / Equity	0.99
Debt / EBITDA	n/a
Debt / FCF	-12.07
Interest Coverage	-5.36

Financial Efficiency

Return on equity (ROE) is -3.49% and return on invested capital (ROIC) is -2.09%.

Return on Equity (ROE)	-3.49%
Return on Assets (ROA)	-1.90%
Return on Invested Capital (ROIC)	-2.09%
Return on Capital Employed (ROCE)	-3.46%
Revenue Per Employee	79.76M
Profits Per Employee	-5.99M
Employee Count	374
Asset Turnover	0.21
Inventory Turnover	1.48

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -47.50% in the last 52 weeks. The beta is 0.31, so Nxera Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.31
52-Week Price Change	-47.50%
50-Day Moving Average	858.96
200-Day Moving Average	1,125.76
Relative Strength Index (RSI)	42.52
Average Volume (20 Days)	854,230

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Nxera Pharma had revenue of JPY 30.87 billion and -2.32 billion in losses. Loss per share was -25.79.

Revenue	30.87B
Gross Profit	22.83B
Operating Income	-4.54B
Pretax Income	-4.02B
Net Income	-2.32B
EBITDA	-457.00M
EBIT	-4.54B
Loss Per Share	-25.79

Full Income Statement

Balance Sheet

The company has 34.47 billion in cash and 66.26 billion in debt, giving a net cash position of -31.80 billion or -353.71 per share.

Cash & Cash Equivalents	34.47B
Total Debt	66.26B
Net Cash	-31.80B
Net Cash Per Share	-353.71
Equity (Book Value)	67.07B
Book Value Per Share	746.05
Working Capital	38.90B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -4.90 billion and capital expenditures -589.00 million, giving a free cash flow of -5.49 billion.

Operating Cash Flow	-4.90B
Capital Expenditures	-589.00M
Free Cash Flow	-5.49B
FCF Per Share	-61.06

Full Cash Flow Statement

Margins

Gross margin is 73.95%, with operating and profit margins of -14.71% and -7.51%.

Gross Margin	73.95%
Operating Margin	-14.71%
Pretax Margin	-13.03%
Profit Margin	-7.51%
EBITDA Margin	-1.48%
EBIT Margin	-14.71%
FCF Margin	n/a

Dividends & Yields

Nxera Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-6.46%
Shareholder Yield	-6.46%
Earnings Yield	-3.09%
FCF Yield	-7.32%

Stock Splits

The last stock split was on June 27, 2018. It was a forward split with a ratio of 4.

Last Split Date	Jun 27, 2018
Split Type	Forward
Split Ratio	4

Scores

Nxera Pharma has an Altman Z-Score of 1.1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.1
Piotroski F-Score	n/a